COR

Business Context and Reporting Period

This Form 10-Q covers the fiscal quarter and six months ended March 31, 2002, for AmerisourceBergen Corporation (now Cencora). The reporting period is heavily influenced by the August 29, 2001, merger of AmeriSource Health Corporation and Bergen Brunswig Corporation. Consequently, historical comparisons for the prior year (2001) reflect only AmeriSource operations, while the current year reflects the combined entity. The Company operates two primary segments: Pharmaceutical Distribution and PharMerica.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 214% year-over-year (YoY) for the quarter and 224% for the six months. On a pro forma basis (combining AmeriSource and Bergen for the prior year), revenue grew 17% for the quarter and 18% for the six months.
• Profitability: Net income increased 192% YoY for the quarter and 177% for the six months. Operating income rose 196% YoY for the quarter.
• Margins: Gross profit margin was 5.19% for the quarter (down from 5.67% pro forma prior year) due to competitive pricing pressures and customer mix changes. Operating expense ratios improved to 3.22% (down from 3.77% pro forma) due to merger integration efficiencies.
• Merger Costs: The Company incurred $4.7 million in merger costs for the quarter and $12.2 million for the six months, primarily for consulting and integration.
• Interest Expense: Increased 178% YoY to $32.7 million for the quarter, driven by higher debt levels associated with the merger, though variable rates decreased.

Outlook, Risks, and Management Commentary

• Merger Integration: Management expects to achieve approximately $150 million in annual synergies by the end of the third year post-merger. Plans include reducing distribution facilities from 51 to approximately 30 over the next 3-4 years.
• Capital Expenditures: Expected to be between $60 million and $70 million for the fiscal year ending September 30, 2002.
• Merger Cost Guidance: Total merger costs for the fiscal year are expected to be between $20 million and $30 million.
• Market Risks: The primary market risk is interest rate fluctuation. The Company holds approximately $1.2 billion in fixed-rate debt and $355 million in variable-rate debt. No hedging instruments were in effect as of March 31, 2002.
• Legal Contingencies: The Company is involved in various antitrust, environmental, and product liability lawsuits (including Proposition 65 claims regarding coal tar and lead). Management does not believe these will have a material adverse effect on financial condition.
• Goodwill: The Company adopted SFAS No. 142, discontinuing goodwill amortization. An initial impairment test was completed with no impairment identified.

Investor Verification Checklist

• Pro Forma Comparability: Verify that year-over-year growth metrics are analyzed on a pro forma basis, as historical 2001 data excludes Bergen Brunswig.
• Merger Synergy Realization: Monitor progress on facility closures and cost savings to ensure the projected $150 million in annual synergies are on track.
• Debt Refinancing: Confirm the refinancing of the $150 million senior notes due in January 2003 and the renewal of the Puerto Rican credit facility.
• Margin Pressure: Assess the impact of competitive pricing and customer mix shifts on gross margins, particularly in the Pharmaceutical Distribution segment.
• Legal Exposure: Review updates on the antitrust class actions and Proposition 65 litigation to ensure no material liabilities have emerged.